

Trials in current drug users and patients on opiate substitution therapy

Alain H. Litwin, MD, MPH

*Albert Einstein College of Medicine
Montefiore Medical Center*

November 3, 2011



Clinic Locations

New
Jersey

The Bronx

Manhattan

1

2

3

4

Key

- 1: Melrose on Track, Melrose 9
- 2: Wellness Center at Port Morris
- 3: Trailer 1, Trailer 2, Van Etten



Integrating HCV Care with Methadone Maintenance Therapy: Results

- Co-located opioid agonist (methadone) and HCV-related care
- Retrospective chart review of on-site HCV treatment (pegylated interferon and ribavirin) provided to 73 drug users from 1/03 – 12/05:
 - 90% IDU
 - 49% recently used illicit drugs
 - 33% with history of alcohol dependence
 - 67% Latino, 21% Caucasian, 12% African American
 - 32% HIV-infected
 - 67% current psychiatric illness
 - 68% genotype 1

Litwin et al, Jour Subs Abuse Treatment, 2009

Integrating HCV Care with Methadone Maintenance Therapy: Results


HCV treatment outcomes:

- 86% completed at least 12 weeks of treatment
- 45% achieved SVR (40% genotype 1)
- HIV/HCV co-infected patients achieved equivalent SVR (43%) as HCV-monoinfected patients (46%)
- No associations between illicit drug use during HCV treatment and HCV virological outcomes, despite high prevalence of active illicit drug use (37%)

Litwin et al, Jour Subs Abuse Treatment, 2009




HCV DOT – ribavirin adherence (n=40)



Week	DOT adherence (%)	TAU adherence (%)
Week 4	90	78
Week 8	89	81
Week 12	88	80
Week 24	87	79

HCV DOT - pegylated interferon adherence (n=40)

- Subjects in both arms received weekly directly administered pegylated interferon
- 96% DOT vs. 94% TAU (p=NS)



HIV DOT: Association between frequent drug use, treatment arm, and adherence (Nahvi et al, DAD 2011)

